Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunocore advances IMCgp100 into clinical trial
IMCgp100 is the first clinical candidate originating from Immunocore’s ImmTAC technology platform which builds on expertise with T cell receptors and has the potential to target a range
IMCgp100 is the first clinical candidate originating from Immunocore’s ImmTAC technology platform which builds on expertise with T cell receptors and has the potential to target a range
The agreement allows Vernalis to receive fees and research milestones and a share in the downstream success of the product in the form of further milestones and royalties
Hydrocodone Polistirex and Chlorpheniramine Polistirex (CIII) ER oral suspension is a generic version of UCB’s Tussionex, which is used for relief of cough and upper respiratory symptoms associated
The patent application covers the combined use of Ampakine compounds and metabotropic glutamate receptor type 5 (mGluR5) antagonists for the treatment of Fragile X syndrome. The investigators from
With the award of the contract, Datatrak is expanding its staff to include experienced clinical data managers to provide services under the direction of Bill Gluck. Datatrak chairman
The company said that the new PowerBar HIGH INTENSITY sustained-release beta alanine tablets mark the entry of the PowerBar brand into the sport dietary supplement category. The product
PolyMedix’s lead small molecule defensin-mimetic antibiotic compound is PMX-30063. PolyMedix’s small molecule defensin-mimetic antimicrobial compounds are designed to mimic human host defense proteins, the body’s natural defense against
Prior to joining NGM Biopharmaceuticals, Rieflin was the president of XenoPort, and currently serves on XenoPort’s board of directors. NGM Biopharmaceuticals chairman David Goeddel said that they are
Convergence Pharmaceuticals has recently raised $35.4m in Series A financing from a syndicate of European and US life science investors. Under the terms of the agreement, Convergence Pharmaceuticals
The company has recruited around 1500 women two months ahead of schedule at over 100 sites throughout the US. Following the completion of the the patient recruitment, Agile